Polycythemia Vera

Continued Hydroxyurea vs Switching to Ruxolitinib for Polycythemia Vera

Continued Hydroxyurea vs Switching to Ruxolitinib for Polycythemia Vera

By

Ruxolitinib is proven superior to best available therapy for polycythemia vera with inadequate response or intolerance of hydroxyurea. This study evaluates the impact of continued hydroxyurea vs switching to ruxolitinib on disease-related symptom burden.

Women With Myeloproliferative Neoplasms Appear to Have Successful Pregnancies

Women With Myeloproliferative Neoplasms Appear to Have Successful Pregnancies

Evidence suggests that women with myeloproliferative neoplasms have a higher risk of maternal and fetal complications. In this data analysis, researchers evaluated outcomes for pregnant women with essential thrombocythemia, polycythemia, or myelofibrosis and their infants.

Polycythemia Vera (Fact Sheet)

Polycythemia Vera (Fact Sheet)

This fact examines the possible causes, risk factors, symptoms, and treatments associated with polycythemia vera.

Hydroxyurea May Improve Kidney Function in PV-Associated Nephrotic Syndrome

Hydroxyurea May Improve Kidney Function in PV-Associated Nephrotic Syndrome

By

The clinical course of a patient with polycythemia vera and proteinuria whose biopsy lead to a diagnosis of focal segmental glomerulosclerosis is described.

Patients With MPNs, Physicians View Treatment Goals Differently

Patients With MPNs, Physicians View Treatment Goals Differently

By

Patients with myeloproliferative neoplasms, such as polycythemia vera and myelofibrosis, and their physicians frequently view the assessment of disease prognosis, disease burden, and treatment goals differently.

Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera

Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera

By

Ruxolitinib is an effective long-term treatment option for patients with polycythemia resistant or intolerant to hydroxyurea, according to a study presented at the 2016 European Hematology Association Congress.

Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera

Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera

[Blood and Lymphatic Cancer: Targets and Therapy] This research provides a summary of the pathobiology of polycythemia vera, and examines challenges associated with traditional PV treatment options and the clinical data for ruxolitinib.

Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera

Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera

By

High platelet counts and hemoglobin/hematocrit levels may be associated with hearing loss in patients with polycythemia vera.

High Symptom Burden With Polycythemia Vera Linked to QoL Impairment

High Symptom Burden With Polycythemia Vera Linked to QoL Impairment

By

Patients with polycythemia vera enrolled in the REVEAL trial have high symptom burden resulting in substantial physical and emotional quality of life impairment and notable work productivity loss.

Study Assesses Risk of Secondary AML in Patients With Myeloproliferative Neoplasms

Study Assesses Risk of Secondary AML in Patients With Myeloproliferative Neoplasms

By

Among patients with myeloproliferative neoplasms, men with primary myelofibrosis diagnosed after 2006 are at the highest risk of developing secondary acute myeloid leukemia (AML).

FDA Approves Ruxolitinib for Polycythemia Vera

FDA Approves Ruxolitinib for Polycythemia Vera

Drug is approved for patients who cannot tolerate or have an inadequate response to other meds.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs